A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Alzheimer s Research & Therapy

Topics

Medicine

Pathology

Physiology

Internal Medicine

Neurology

Show all topics

DOI

10.1186/s13195-021-00813-8

License

CC-BY

Other Formats

PDF